Cellectis (CLLS) versus Editas Medicine (EDIT) Head-To-Head Comparison
Cellectis (NASDAQ:CLLS) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.
Volatility and Risk
Cellectis has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.56, suggesting that its share price is 156% more volatile than the S&P 500.
28.4% of Cellectis shares are held by institutional investors. Comparatively, 69.1% of Editas Medicine shares are held by institutional investors. 16.4% of Cellectis shares are held by insiders. Comparatively, 5.2% of Editas Medicine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Cellectis and Editas Medicine’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cellectis||$33.72 million||21.11||-$99.36 million||($2.78)||-6.15|
|Editas Medicine||$13.73 million||70.65||-$120.32 million||($2.98)||-6.81|
Cellectis has higher revenue and earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.
This table compares Cellectis and Editas Medicine’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and target prices for Cellectis and Editas Medicine, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cellectis presently has a consensus price target of $48.00, indicating a potential upside of 180.54%. Editas Medicine has a consensus price target of $45.29, indicating a potential upside of 123.19%. Given Cellectis’ stronger consensus rating and higher probable upside, analysts clearly believe Cellectis is more favorable than Editas Medicine.
Cellectis beats Editas Medicine on 10 of the 14 factors compared between the two stocks.
Cellectis S.A., a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL). The company's products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-ALL. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc; Les Laboratoires Servier SAS; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia, as well as a partnership agreement with the Wyss Institute for Biologically Inspired Engineering at Harvard University. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
About Editas Medicine
Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. It develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. The company also develops other therapies for eye diseases, such as Herpes Simplex Virus 1 that causes lifelong infections primarily leading to ocular and oral disease; and Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss. In addition, it develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited for the research and development of medicines for ocular diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.